Guyana introduces 9-valent HPV vaccine

– takes major step toward eliminating cervical cancer

Guyana is now one step closer to eliminating cervical cancer following the nationwide launch of the 9-valent Human Papillomavirus (HPV) vaccine.
In 2020, uptake of the HPV vaccine in Guyana was approximately 17 percent. However, following several vaccination campaigns, this figure has increased to 71 percent. According to the World Health Organisation (WHO), the ideal target is 90 percent coverage.
Cervical cancer is currently the second most common cancer affecting people in Guyana. Globally, the disease is responsible for approximately 44,000 deaths each year.
In response, Guyana is intensifying efforts to prevent it. HPV, one of the most common sexually transmitted infections worldwide, is known to cause a range of cancers and warts in both men and women. As such, individuals aged nine and older are strongly encouraged to get vaccinated to help prevent infection.
Speaking at the launch ceremony held at the Diamond Regional Hospital, Minister of Health Dr Frank Anthony emphasised the vaccine’s significance in the country’s national cancer prevention strategy.
“We now have the 9-valent vaccine available to our population. HPV screening is accessible to women between the ages of 21 and 65. If we find any abnormal changes, we follow a clinical protocol – this includes Pap smears and any further tests required. The next stage is ensuring treatment is readily available,” Dr Anthony said.
He described the vaccine as a “scientific triumph,” adding that it is safe, effective, and long-lasting. Clinical trials and real-world studies have shown high seroconversion rates from HPV vaccination, which refers to the development of antibodies in response to the vaccine.
Dr Anthony also announced plans for the government to construct and staff a dedicated cancer treatment facility in Guyana.
“In the very near future, we’ll begin building and staffing a facility so that people in Guyana affected by different types of cancer can receive care right here in the country,” he stated.
“We are working to change patient outcomes. And since cervical cancer is preventable, we strongly believe that using this vaccine will lead to even better results. I’m hopeful we can move from 71 percent national coverage to 90 percent using the 9-valent vaccine. This would have a very positive impact on our population.”
He also stressed the importance of sustaining the effort and expressed gratitude to the Ministry of Health’s staff for their dedication and swift implementation of the programme.
Although the 9-valent HPV vaccine is widely used in developed countries, it is expensive to procure. Guyana was able to purchase the vaccine with support from PAHO, which sourced it from manufacturer Merck & Co., saving the country approximately GY$17 million.
Anyone interested in receiving the vaccine can do so at health centres across Guyana. Children aged 9 to 15 will receive two doses, while individuals aged 16 and older will receive three doses. Persons who previously received the quadrivalent HPV vaccine are also eligible to receive the 9-valent version.